Test Price
450 AED✅ Home Collection Available
Immunohistochemistry Myeloperoxidase MPO Test in UAE Diagnostic Pathology 450 AED
Executive Summary & Core Metrics
- Accuracy Guarantee 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited immunohistochemistry processing on archival solid tissue specimens.
- Specimen Logistics Secure Medical Courier Solid Tissue Specimen Retrieval for FFPE blocks and formalin-fixed tissue; retrieval coordinated directly with the referring hospital pathology department.
- Clinical Guidance Post-test telephonic interpretation session with a DHA-licensed pathologist to integrate MPO results with full morphological and molecular findings.
- Insurance & Billing Direct insurance verification via WhatsApp at +971 54 548 8731 — instant pre-approval for most major UAE networks.
Test Overview & Methodology
The Immunohistochemistry Myeloperoxidase MPO test detects the MPO enzyme in formalin-fixed paraffin-embedded tissue to confirm myeloid lineage in acute leukemias and myeloproliferative neoplasms. This is the gold-standard morphological method for the differential diagnosis of poorly differentiated hematopoietic malignancies.
MPO expression is specific to cells of neutrophil lineage and their precursors, making this stain indispensable for classifying acute myeloid leukemia and distinguishing myeloid sarcomas from lymphoid or undifferentiated neoplasms. Results are interpreted alongside a complete panel of lineage-defining markers.
| Feature | Our MPO IHC Test | Flow Cytometry MPO |
|---|---|---|
| Methodology | Immunohistochemistry on FFPE tissue | Fluorescence-based detection on fresh cell suspension |
| TAT Routine | 5 working days | 1 to 2 days requires immediate sample processing |
| Morphologic Correlation | Direct visualisation of tumour tissue architecture | Limited to single-cell suspension no tissue context |
| Sample Type | FFPE block or formalin-fixed tissue | Fresh bone marrow or blood in special transport medium |
| Clinical Use | Myeloid lineage determination in solid tissue biopsies | Routine immunophenotyping of liquid haematological samples |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor DHA 61713011 Specialist Diagnostic Radiology
A positive MPO immunohistochemistry stain provides strong evidence of myeloid differentiation, but no single marker should be interpreted in isolation. I advise referring clinicians to review MPO results in the context of morphology, CD34 and CD117 expression, and cytogenetic or molecular profiling. A negative MPO result does not rule out myeloid neoplasia, particularly in poorly differentiated or therapy-related cases where antigen loss may occur.
Critical Safety Advisory
Do Not Alter Prescribed Therapy
Do not discontinue or modify any prescribed medication including chemotherapy or anticoagulants without explicit instruction from your supervising consultant. Biopsy guidance and MPO result interpretation must be integrated into your overall treatment plan. Abrupt changes to therapy can lead to disease progression or haemorrhagic complications.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Uncontrolled bleeding diathesis, anticoagulation that cannot be paused for biopsy, or insufficient tissue in the provided block fewer than 5 tissue sections available.
- Exclusion Minors: In accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability, patients under 18 require a custodial consent form and a paediatric oncologist referral.
- Urgent signs: If you develop fever above 38 degrees Celsius, uncontrolled bleeding at the biopsy site, or sudden severe pain, proceed immediately to the emergency department. Do not wait for test results if you feel acutely unwell.
Patient FAQ & Clinical Guidance
1. What does a positive MPO immunohistochemistry stain mean for my diagnosis?
Positive MPO staining confirms that your tumour cells originate from the myeloid lineage, which helps classify leukemias such as acute myeloid leukemia. This enzyme is specific to neutrophils and their precursors, so a positive result identifies acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms with granulocytic differentiation. Your oncologist will combine this with other markers including CD34 and CD117 to finalise the subtype.
2. Can this MPO test be performed on any body site or only on bone marrow?
MPO immunohistochemistry can be performed on formalin-fixed paraffin-embedded tissue from virtually any anatomical site including lymph nodes, spleen, or extramedullary myeloid sarcoma. Unlike flow cytometry which often requires fresh bone marrow aspirate, this method works on archived biopsy blocks enabling retrospective analysis and correlation with tissue architecture. Your doctor must provide the site and clinical history for accurate interpretation.
3. How accurate is immunohistochemistry for MPO compared with genetic tests?
Immunohistochemistry for MPO offers greater than 95 percent concordance with genetic myeloid markers and directly visualises protein expression within tissue, making it essential for morphologic diagnosis. While next-generation sequencing detects mutations such as NPM1 or FLT3, MPO IHC establishes lineage commitment that genetic data alone cannot guarantee. The two methods are complementary and a combined approach gives the most robust diagnosis under UAE MOHAP guidelines.
4. How should I prepare my archived tissue block for shipping to the laboratory?
No preparation is required on your part. Our Secure Medical Courier Solid Tissue Specimen Retrieval service coordinates directly with your hospital pathology department to obtain the FFPE block or representative sections. The courier uses temperature-controlled packaging to preserve tissue integrity during transit. Please ensure your referring physician has completed the test requisition form with relevant clinical history and site of biopsy.
UAE Regulatory & Data Privacy Adherence
- All patient data processed under Federal Decree-Law No. 45 of 2021 on Personal Data Protection PDPL with encrypted storage and controlled access protocols.
- Clinical testing safety and patient consent governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Health data handling complies with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Laboratory accredited under ISO 9001:2015 certification ensuring rigorous quality management and continuous audit compliance.
Clinical & Logistical Metadata
| Test Name | Immunohistochemistry Myeloperoxidase MPO |
| Price AED | 450 AED inclusive of all handling and courier retrieval fees |
| Turnaround Time | 5 working days from receipt of tissue block at laboratory |
| Sample Type Matrix | Archival Tissue Specimen FFPE block or formalin-fixed tissue sections |
| Methodology Used | Immunohistochemistry on FFPE tissue with automated staining and haematoxylin counterstain |
| ICD-10-CM Code | C92.00, C92.40, D71 |
| LOINC Code | 58420-9 |
| DHA Facility License & Address | License 1143 | Premises 105 Floor 1 Building 33 Dubai Healthcare City Dubai UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians